Modified Vaccinia Ankara Based SARS-CoV-2 Vaccine Expressing Full-Length Spike Induces Strong Neutralizing Antibody Response
View ORCID ProfileNanda Kishore Routhu, View ORCID ProfileSailaja Gangadhara, View ORCID ProfileNarayanaiah Cheedarla, Ayalnesh Shiferaw, View ORCID ProfileSheikh Abdul Rahman, Anusmita Sahoo, Pei-Yong Shi, View ORCID ProfileVineet D Menachery, Katharine Floyd, View ORCID ProfileStephanie Fischinger, View ORCID ProfileCaroline Atyeo, View ORCID ProfileGalit Alter, View ORCID ProfileMehul S Suthar, View ORCID ProfileRama Rao Amara
doi: https://doi.org/10.1101/2020.06.27.175166
Abstract
There is a great need for the development of vaccines for preventing SARS-CoV-2 infection and mitigating the COVID-19 pandemic. Here, we developed two modified vaccinia Ankara (MVA) based vaccines which express either a membrane anchored full-length spike protein (MVA/S) stabilized in a prefusion state or the S1 region of the spike (MVA/S1) which forms trimers and is secreted. Both immunogens contained the receptor-binding domain (RBD) which is a known target of antibody-mediated neutralization. Following immunizations with MVA/S or MVA/S1, both spike protein recombinants induced strong IgG antibodies to purified full-length SARS-CoV-2 spike protein. The MVA/S induced a robust antibody response to purified RBD, S1 and S2 whereas MVA/S1 induced an antibody response to the S1 region outside of the RBD region. Both vaccines induced an antibody response in the lung and that was associated with induction of bronchus-associated lymphoid tissue. MVA/S but not MVA/S1 vaccinated mice generated robust neutralizing antibody responses against SARS-CoV-2 that strongly correlated with RBD antibody binding titers. Mechanistically, S1 binding to ACE-2 was strong but reduced following prolonged pre-incubation at room temperature suggesting confirmation changes in RBD with time. These results demonstrate MVA/S is a potential vaccine candidate against SARS-CoV-2 infection.
